Evidence map›Paper›PMID 29499679›Full record

ArticleBMC complementary and alternative medicine2018

Phytochemical profiling and in vitro screening for anticholinesterase, antioxidant, antiglucosidase and neuroprotective effect of three traditional medicinal plants for Alzheimer's Disease and Diabetes Mellitus dual therapy.

Mohan Penumala, Raveendra Babu Zinka, Jeelan Basha Shaik, Suresh Kumar Reddy Mallepalli, Ramakrishna Vadde, Damu Gangaiah Amooru

Open access · goldAbstract read
In one paragraph

Article in BMC complementary and alternative medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Exploring beetroot (RSC advances · 2024
    Article
  6. Review
  7. Exploring the therapeutic mechanism of potential phytocompounds fromSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024
    Article
  8. Article
  9. Article
  10. Article
  11. Frontiers in nutrition · 2022
    Article
  12. Review
  13. Article
  14. Neuroprotective, antidiabetic and antioxidant effect of Hedera nepalensis and lupeol against STZ + AlClDaru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2018
    Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Mohan PenumalaDepartment of Chemistry, Yogi Vemana University, Kadapa, Andhra Pradesh, India.
Raveendra Babu ZinkaDepartment of Chemistry, Yogi Vemana University, Kadapa, Andhra Pradesh, India.
Jeelan Basha ShaikDepartment of Chemistry, Yogi Vemana University, Kadapa, Andhra Pradesh, India.
Suresh Kumar Reddy MallepalliDepartment of Biotechnology and Bioinformatics, Yogi Vemana University, Kadapa, Andhra Pradesh, India.
Ramakrishna VaddeDepartment of Biotechnology and Bioinformatics, Yogi Vemana University, Kadapa, Andhra Pradesh, India.
Damu Gangaiah AmooruDepartment of Chemistry, Yogi Vemana University, Kadapa, Andhra Pradesh, India. agdamu01@gmail.com.ORCID http://orcid.org/0000-0002-6578-3232
Yogi Vemana University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundExtensive epidemiological and clinical studies revealed that Alzheimer's Disease (AD) and Type 2 Diabetes Mellitus (T2D) are most likely to appear simultaneously in aged people as T2D is a major risk factor for AD. Therefore, development of potential multifunctional agents for dual therapy of AD and T2D has received much attention. Buchanania axillaris, Hemidesmus indicus and Rhus mysorensis have been used extensively in popular medicine. The present study was aimed at phytochemical profiling and evaluating multifunctional ability of titled plants in the AD and T2D dual therapy.

methodsMethanolic extracts and their derived fractions were evaluated for their inhibitory capacities against acetylcholinesterase (AChE) & butyrylcholinesterase (BuChE), and α- & β-glucosidase besides kinetic analysis of inhibition using methods of Elmann and Shibano, respectively. Antioxidant potency of active fractions was assessed by their DPPH and ABTS radical scavenging activities. Active fractions were tested by the MTT assay to verify cytotoxicity and neuroprotective ability in human nueroblastoma cell lines. Phytochemical screening was done with the aid of spectrophotometric methods.

resultsAll the methanolic extracts of test plants (BAM, HIM, RMM) showed concentration dependent inhibitory activities against AChE, BuChE, α- and β-glucosidase enzymes. Subsequent fractionation and evaluation revealed that chloroform fractions BAC, HIC and RMC with IC

conclusionThe strong anticholinesterase, antiglucosidase, antioxidant and neuroprotective activities of methanolic extracts and their derived chloroform fractions indicate the potential of Buchanania axillaris, Hemidesmus indicus and Rhus mysorensis as multifunctional therapeutic remedies for the dual therapy of T2D and AD.

Indexed as

AcetylcholinesteraseAlzheimer DiseaseAntioxidantsButyrylcholinesteraseCell LineCholinesterase InhibitorsDiabetes Mellitus, Type 2Drug Evaluation, PreclinicalGlucosidasesHumansKineticsNeuroprotective AgentsPlant ExtractsPlants, MedicinalAcetylcholinesteraseAntioxidantsButyrylcholinesteraseCholinesterase InhibitorsGlucosidasesNeuroprotective AgentsPlant ExtractsAnticholinesterase activityAntidiabetic activityAntioxidant activityBuchanania axillarisHemidesmus indicusPhytochemical profileRhus mysorensis

Identifiers

PMID29499679
PMCPMC5834903
OpenAlexW2797094977

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.